Stay updated with breaking news from Low risk trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CRT 2024: Evolut TAVR is a safe, effective, and economically cost-effective treatment option for low-risk severe aortic stenosis patients compared to surgery up to four years ....
Medtronic plc announced four-year results from the Evolut Low Risk Trial. The Medtronic Evolut? transcatheter aortic valve replacement system demonstrated exceptional outcomes and sustained valve. ....
/PRNewswire/ Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced four-year results from the Evolut Low Risk Trial. The. ....
TCT 2023: Medtronic adds to the body of evidence for Evolut TAVR with late-breaking clinical trial data from the Evolut Low Risk TrialDUBLIN and S. ....